Publication: Target blood pressure and control status in Asia
Issued Date
2020-03-01
Resource Type
ISSN
17517176
15246175
15246175
Other identifier(s)
2-s2.0-85075450586
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Hypertension. Vol.22, No.3 (2020), 344-350
Suggested Citation
Yook Chin Chia, Kazuomi Kario, Yuda Turana, Jennifer Nailes, Jam Chin Tay, Saulat Siddique, Sungha Park, Jinho Shin, Peera Buranakitjaroen, Chen Huan Chen, Romeo Divinagracia, Satoshi Hoshide, Huynh Van Minh, Jorge Sison, Arieska Ann Soenarta, Guru Prasad Sogunuru, Apichard Sukonthasarn, Boon Wee Teo, Narsingh Verma, Yuqing Zhang, Tzung Dau Wang, Ji Guang Wang Target blood pressure and control status in Asia. Journal of Clinical Hypertension. Vol.22, No.3 (2020), 344-350. doi:10.1111/jch.13714 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/54630
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Target blood pressure and control status in Asia
Author(s)
Yook Chin Chia
Kazuomi Kario
Yuda Turana
Jennifer Nailes
Jam Chin Tay
Saulat Siddique
Sungha Park
Jinho Shin
Peera Buranakitjaroen
Chen Huan Chen
Romeo Divinagracia
Satoshi Hoshide
Huynh Van Minh
Jorge Sison
Arieska Ann Soenarta
Guru Prasad Sogunuru
Apichard Sukonthasarn
Boon Wee Teo
Narsingh Verma
Yuqing Zhang
Tzung Dau Wang
Ji Guang Wang
Kazuomi Kario
Yuda Turana
Jennifer Nailes
Jam Chin Tay
Saulat Siddique
Sungha Park
Jinho Shin
Peera Buranakitjaroen
Chen Huan Chen
Romeo Divinagracia
Satoshi Hoshide
Huynh Van Minh
Jorge Sison
Arieska Ann Soenarta
Guru Prasad Sogunuru
Apichard Sukonthasarn
Boon Wee Teo
Narsingh Verma
Yuqing Zhang
Tzung Dau Wang
Ji Guang Wang
Other Contributor(s)
University Medicine and Pharmacy, Hue University
De La Salle Health Sciences Institute
Sunway University
Hanyang University Medical Center
Jichi Medical University
Yonsei University Health System
Shanghai Jiao Tong University School of Medicine
Madras Institute of Orthopaedics and Traumatology Hospitals
National Taiwan University Hospital
Kathmandu University
University of the East Ramon Magsaysay Memorial Medical Center
Fatima Memorial Hospital
National Yang-Ming University Taiwan
Universitas Katolik Indonesia Atma Jaya
Universitas Indonesia
University of Malaya
Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Yong Loo Lin School of Medicine
King George's Medical University
Faculty of Medicine, Siriraj Hospital, Mahidol University
Tan Tock Seng Hospital
Bangkok Hospital Chiang Mai
De La Salle Health Sciences Institute
Sunway University
Hanyang University Medical Center
Jichi Medical University
Yonsei University Health System
Shanghai Jiao Tong University School of Medicine
Madras Institute of Orthopaedics and Traumatology Hospitals
National Taiwan University Hospital
Kathmandu University
University of the East Ramon Magsaysay Memorial Medical Center
Fatima Memorial Hospital
National Yang-Ming University Taiwan
Universitas Katolik Indonesia Atma Jaya
Universitas Indonesia
University of Malaya
Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Yong Loo Lin School of Medicine
King George's Medical University
Faculty of Medicine, Siriraj Hospital, Mahidol University
Tan Tock Seng Hospital
Bangkok Hospital Chiang Mai
Abstract
© 2019 Wiley Periodicals, Inc. It is widely accepted that hypertension constitutes a significant cardiovascular risk factor and that treating high blood pressure (BP) effectively reduces cardiovascular risk. An important issue in Asia is not just the high prevalence of hypertension, particularly in some countries, but also the low level of awareness and treatment rates in many regions. The 2017 update of the American College of Cardiology/American Heart Association hypertension guidelines raised the question about which BP threshold should be used to diagnose and treat hypertension. Although there is a theoretical rationale for a stricter BP criterion in Asia given the ethnic-specific features of hypertension in the region, the majority of countries in Asia have retained a diagnostic BP threshold of ≥140/90 mm Hg. Although lowering thresholds might make theoretical sense, this would increase the prevalence of hypertension and also markedly reduce BP control rates. In addition, there are currently no data from robust randomized clinical trials of the benefits of the lower targets in preventing cardiovascular disease and reducing cardiovascular risk, particularly in high-risk patients and especially for Asian populations. There is also no defined home BP treatment target level for an office BP treatment target of 130/80 mm Hg. However, in this regard, in the interim, lifestyle modifications, including reducing body weight and salt intake, should form an important part of hypertension management strategies in Asia, while studies on treating at lower BP threshold level in Asians and getting to lower BP targets will be helpful to inform and optimize the management of hypertension in the region.